Our studies indicate that Her2-overexpressing breast cancer cells are very sensitive to AA and that combined treatment of these patients with doxorubicin with judicious increases in the Ω-6 fatty acid content of the diet during dox chemotherapy could improve treatment efficacy without exacerbating cardiotoxicity. Here, ERBB2 is linked to breast carcinoma.